MAP3K8 and chronic myelogenous leukemia, BCR-ABL1 positive: Second, we did not use CML cells from patients with dasatinib‐resistant CML overexpressing MOS and TPL2 to confirm whether the abrogation of MOS, TPL2 and ERK1/2 overcomes dasatinib resistance.